A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Study not startet. PI not working at the Universityhospital of North Norway
unable to obtain samples of key groups to do any analysis.
Enrolment terminated early owing to slow accrual (repeat-biopsy burden and COVID-19 pandemic), following a protocol-specified interim analysis approved by the ethics committee (2017-050(5)).
After further evaluation, the secondary data source was determined to be insufficient to address the study objectives. No prospective patient enrollment was planned, and the study was not initiated.
After further evaluation, the secondary data source was determined to be insufficient to address the study objectives. No prospective patient enrollment was planned, and the study was not initiated
We do not have active funding.
Slow accrual.
Temporarily closed to enrollment as the company that provided the hyperspectral imaging camera to previous PI had new PI return the devices. Since study is unfunded, currently investigating rental cost of the device.
no more patients corresponding to the criteriae
Study was not initiated due to operational and feasibility constraints; no participants were enrolled.
Administrative
Continuing to pursue additional funding to continue with the study
38 approvals month-to-date.
No data.
7.5% of the last year's EMA authorisations were conditional.
| Medicine | Authorised |
|---|---|
| Nezglyal | 2026-09-21 |
1 new · 0 resolved · 103 currently active.
| Newly reported shortage | Posted |
|---|---|
| Arsenic Trioxide Injection | 2026-09-21 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 90,195 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Assiut University | 4,929 |
| Cairo University | 4,864 |
| GlaxoSmithKline | 3,638 |
| Assistance Publique - Hôpitaux de Paris | 3,562 |
| National Cancer Institute (NCI) | 3,553 |
| AstraZeneca | 3,486 |
| Pfizer | 3,311 |
| Mayo Clinic | 3,253 |
| M.D. Anderson Cancer Center | 3,031 |
| Novartis Pharmaceuticals | 2,705 |
| National Taiwan University Hospital | 2,605 |
| Massachusetts General Hospital | 2,574 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,441 |
| Boehringer Ingelheim | 2,291 |
| University of California, San Francisco | 2,164 |
| Riphah International University | 2,158 |
| Stanford University | 2,156 |
| Merck Sharp & Dohme LLC | 2,149 |
| Hoffmann-La Roche | 2,091 |
| Eli Lilly and Company | 2,087 |
| Duke University | 2,056 |
| Memorial Sloan Kettering Cancer Center | 1,952 |
| Ain Shams University | 1,904 |
| Seoul National University Hospital | 1,893 |
| Hospices Civils de Lyon | 1,847 |
| Condition | Trials |
|---|---|
| breast cancer | 11,918 |
| obesity disorder | 9,724 |
| type 2 diabetes mellitus | 9,222 |
| chronic pain syndrome | 8,907 |
| cancer | 8,399 |
| HIV infectious disease | 8,260 |
| COVID-19 | 7,660 |
| non-small cell lung carcinoma | 6,469 |
| hypertensive disorder | 6,185 |
| diabetes mellitus | 6,175 |
| colorectal cancer | 6,095 |
| cerebrovascular disorder | 6,088 |
| coronary artery disorder | 5,994 |
| prostate cancer | 5,908 |
| depressive disorder | 5,893 |
| cardiovascular disorder | 5,644 |
| anxiety disorder | 5,001 |
| heart failure | 4,953 |
| injury | 4,546 |
| Parkinson disease | 4,495 |
| asthma | 4,456 |
| cognitive disorder | 4,244 |
| lung cancer | 4,094 |
| neuralgia | 3,912 |
| benign essential hypertension | 3,729 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,258 |
| paclitaxel | 5,639 |
| isoniazid | 5,382 |
| prednisolone | 5,356 |
| cyclophosphamide | 5,158 |
| ropivacaine | 4,959 |
| dexamethasone | 4,860 |
| bevacizumab | 4,693 |
| cisplatin | 4,539 |
| lidocaine | 3,697 |
| aspirin | 3,439 |
| gemcitabine | 3,239 |
| bupivacaine | 3,204 |
| pembrolizumab | 3,033 |
| metformin | 3,020 |
| desoxycorticosterone acetate | 2,994 |
| sitagliptin and metformin hydrochloride | 2,979 |
| rituximab | 2,966 |
| meprednisone | 2,850 |
| sitagliptin metformin hydrochloride | 2,791 |
| dapagliflozin metformin hydrochloride | 2,788 |
| docetaxel | 2,786 |
| linagliptin and metformin hydrochloride | 2,778 |
| fluorouracil | 2,766 |
| alogliptin and metformin hydrochloride | 2,720 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,096 | 862 | 900 |
| AstraZeneca | 1,023 | 552 | 810 |
| Pfizer | 1,177 | 710 | 668 |
| Novartis Pharmaceuticals | 512 | 841 | 738 |
| Boehringer Ingelheim | 1,074 | 321 | 400 |
| Merck Sharp & Dohme LLC | 702 | 552 | 744 |
| Hoffmann-La Roche | 495 | 483 | 573 |
| Eli Lilly and Company | 836 | 536 | 550 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Miglustat | 2026-09-28 |
| Atogepant | 2026-09-28 |
| Technetium Tc-99m Labeled Carbon | 2026-09-29 |
| Patiromer Sorbitex Calcium | 2026-10-02 |
| Risdiplam | 2026-10-03 |
| Dexamethasone | 2026-10-03 |
| Afamelanotide | 2026-10-08 |
| Binimetinib | 2026-10-11 |
| Pilocarpine Hydrochloride | 2026-10-17 |
| Acetaminophen; Ibuprofen Sodium | 2026-10-17 |
| Tenapanor Hydrochloride | 2026-10-17 |
| Treprostinil Diolamine | 2026-10-18 |
| Edoxaban Tosylate | 2026-10-18 |
| Adapalene; Benzoyl Peroxide; Clindamycin Phosphate | 2026-10-20 |
| Ivabradine | 2026-10-22 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.